NYSE:NVS

Novartis Competitors

$92.39
+0.20 (+0.22 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$92.30
$92.92
50-Day Range
$88.02
$94.15
52-Week Range
$77.04
$98.52
Volume1.39 million shs
Average Volume1.60 million shs
Market Capitalization$211.45 billion
P/E Ratio23.39
Dividend Yield2.26%
Beta0.55

Novartis (NYSE:NVS) Vs. JNJ, PFE, LLY, NVO, ABT, and ABBV

Should you be buying NVS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Novartis, including Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), and AbbVie (ABBV).

Johnson & Johnson (NYSE:JNJ) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings and institutional ownership.

Profitability

This table compares Johnson & Johnson and Novartis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson19.92%37.78%14.12%
Novartis17.83%25.25%10.74%

Earnings & Valuation

This table compares Johnson & Johnson and Novartis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.58 billion5.49$14.71 billion$8.0321.44
Novartis$48.66 billion4.35$8.07 billion$5.7516.07

Johnson & Johnson has higher revenue and earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

66.6% of Johnson & Johnson shares are owned by institutional investors. Comparatively, 9.5% of Novartis shares are owned by institutional investors. 0.3% of Johnson & Johnson shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Johnson & Johnson has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Johnson & Johnson and Novartis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson02702.78
Novartis24502.27

Johnson & Johnson presently has a consensus price target of $190.3750, indicating a potential upside of 10.55%. Novartis has a consensus price target of $108.50, indicating a potential upside of 17.44%. Given Novartis' higher possible upside, analysts plainly believe Novartis is more favorable than Johnson & Johnson.

Dividends

Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.5%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has increased its dividend for 59 consecutive years and Novartis has increased its dividend for 1 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Johnson & Johnson beats Novartis on 15 of the 17 factors compared between the two stocks.

Novartis (NYSE:NVS) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Risk and Volatility

Novartis has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Novartis and Pfizer, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24502.27
Pfizer010202.17

Novartis presently has a consensus price target of $108.50, suggesting a potential upside of 17.44%. Pfizer has a consensus price target of $43.0833, suggesting a potential upside of 0.64%. Given Novartis' stronger consensus rating and higher possible upside, analysts clearly believe Novartis is more favorable than Pfizer.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.6%. Novartis pays out 36.2% of its earnings in the form of a dividend. Pfizer pays out 70.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has raised its dividend for 1 consecutive years and Pfizer has raised its dividend for 1 consecutive years.

Profitability

This table compares Novartis and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis17.83%25.25%10.74%
Pfizer23.06%26.93%10.83%

Insider & Institutional Ownership

9.5% of Novartis shares are held by institutional investors. Comparatively, 64.1% of Pfizer shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Novartis and Pfizer's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$48.66 billion4.35$8.07 billion$5.7516.07
Pfizer$41.91 billion5.72$9.62 billion$2.2219.28

Pfizer has lower revenue, but higher earnings than Novartis. Novartis is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Summary

Pfizer beats Novartis on 9 of the 16 factors compared between the two stocks.

Novartis (NYSE:NVS) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.4%. Novartis pays out 36.2% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has raised its dividend for 1 consecutive years and Eli Lilly and has raised its dividend for 1 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Institutional & Insider Ownership

9.5% of Novartis shares are held by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Novartis and Eli Lilly and's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$48.66 billion4.35$8.07 billion$5.7516.07
Eli Lilly and$24.54 billion9.52$6.19 billion$7.9330.71

Novartis has higher revenue and earnings than Eli Lilly and. Novartis is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Novartis and Eli Lilly and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24502.27
Eli Lilly and021112.93

Novartis presently has a consensus price target of $108.50, indicating a potential upside of 17.44%. Eli Lilly and has a consensus price target of $231.2857, indicating a potential downside of 5.02%. Given Novartis' higher probable upside, equities analysts plainly believe Novartis is more favorable than Eli Lilly and.

Profitability

This table compares Novartis and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis17.83%25.25%10.74%
Eli Lilly and23.91%132.28%16.36%

Volatility & Risk

Novartis has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.

Summary

Eli Lilly and beats Novartis on 11 of the 17 factors compared between the two stocks.

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Volatility & Risk

Novo Nordisk A/S has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.

Institutional & Insider Ownership

5.6% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 9.5% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.4%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S has raised its dividend for 1 consecutive years and Novartis has raised its dividend for 1 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Profitability

This table compares Novo Nordisk A/S and Novartis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novo Nordisk A/S33.77%71.90%30.84%
Novartis17.83%25.25%10.74%

Earnings & Valuation

This table compares Novo Nordisk A/S and Novartis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$19.45 billion11.21$6.46 billion$2.7633.55
Novartis$48.66 billion4.35$8.07 billion$5.7516.07

Novartis has higher revenue and earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Novo Nordisk A/S and Novartis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novo Nordisk A/S23302.13
Novartis24502.27

Novartis has a consensus price target of $108.50, indicating a potential upside of 17.44%. Given Novartis' stronger consensus rating and higher probable upside, analysts plainly believe Novartis is more favorable than Novo Nordisk A/S.

Summary

Novartis beats Novo Nordisk A/S on 10 of the 16 factors compared between the two stocks.

Novartis (NYSE:NVS) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, profitability and dividends.

Institutional and Insider Ownership

9.5% of Novartis shares are held by institutional investors. Comparatively, 73.0% of Abbott Laboratories shares are held by institutional investors. 0.0% of Novartis shares are held by insiders. Comparatively, 1.5% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Novartis and Abbott Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis24502.27
Abbott Laboratories121302.75

Novartis presently has a consensus target price of $108.50, indicating a potential upside of 17.44%. Abbott Laboratories has a consensus target price of $124.6667, indicating a potential upside of 3.05%. Given Novartis' higher possible upside, analysts clearly believe Novartis is more favorable than Abbott Laboratories.

Profitability

This table compares Novartis and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis17.83%25.25%10.74%
Abbott Laboratories15.85%27.00%12.39%

Earnings & Valuation

This table compares Novartis and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$48.66 billion4.35$8.07 billion$5.7516.07
Abbott Laboratories$34.61 billion6.21$4.50 billion$3.6533.15

Novartis has higher revenue and earnings than Abbott Laboratories. Novartis is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Novartis has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Dividends

Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.5%. Novartis pays out 36.2% of its earnings in the form of a dividend. Abbott Laboratories pays out 49.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 49 consecutive years. Novartis is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Abbott Laboratories beats Novartis on 10 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Analyst Recommendations

This is a summary of current ratings for AbbVie and Novartis, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie111202.79
Novartis24502.27

AbbVie presently has a consensus target price of $121.6733, suggesting a potential upside of 4.62%. Novartis has a consensus target price of $108.50, suggesting a potential upside of 17.44%. Given Novartis' higher probable upside, analysts plainly believe Novartis is more favorable than AbbVie.

Profitability

This table compares AbbVie and Novartis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie10.28%136.75%12.95%
Novartis17.83%25.25%10.74%

Insider & Institutional Ownership

66.0% of AbbVie shares are owned by institutional investors. Comparatively, 9.5% of Novartis shares are owned by institutional investors. 0.1% of AbbVie shares are owned by company insiders. Comparatively, 0.0% of Novartis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Novartis pays an annual dividend of $2.08 per share and has a dividend yield of 2.3%. AbbVie pays out 49.2% of its earnings in the form of a dividend. Novartis pays out 36.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years and Novartis has raised its dividend for 1 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Earnings and Valuation

This table compares AbbVie and Novartis' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$45.80 billion4.48$4.62 billion$10.5611.01
Novartis$48.66 billion4.35$8.07 billion$5.7516.07

Novartis has higher revenue and earnings than AbbVie. AbbVie is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AbbVie has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Summary

AbbVie beats Novartis on 12 of the 17 factors compared between the two stocks.


Novartis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.6$172.20+0.0%$453.47 billion$82.58 billion25.89Analyst Report
Pfizer logo
PFE
Pfizer
2.8$42.81+0.0%$239.64 billion$41.91 billion18.37Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.9$243.50+0.8%$233.52 billion$24.54 billion36.40Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.5$92.60+1.3%$218.05 billion$19.45 billion32.15Upcoming Earnings
Abbott Laboratories logo
ABT
Abbott Laboratories
2.9$120.98+0.1%$214.96 billion$34.61 billion34.08Insider Selling
Short Interest Decrease
AbbVie logo
ABBV
AbbVie
3.2$116.30+2.2%$205.41 billion$45.80 billion41.10Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.8$76.87+0.1%$194.64 billion$47.99 billion35.10Earnings Announcement
Dividend Announcement
Analyst Report
Analyst Revision
News Coverage
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.5$67.87+0.4%$150.81 billion$42.52 billion-29.90Earnings Announcement
Analyst Report
Short Interest Increase
Analyst Revision
AstraZeneca logo
AZN
AstraZeneca
2.4$57.24+0.7%$150.23 billion$26.62 billion39.75Earnings Announcement
Dividend Cut
Analyst Revision
Sanofi logo
SNY
Sanofi
1.9$51.56+0.1%$129.82 billion$41.17 billion18.75Earnings Announcement
Analyst Report
Short Interest Decrease
News Coverage
GlaxoSmithKline logo
GSK
GlaxoSmithKline
2.1$40.14+0.1%$108.08 billion$43.79 billion16.94
Zoetis logo
ZTS
Zoetis
2.3$202.70+0.7%$96.24 billion$6.68 billion54.64Upcoming Earnings
Short Interest Decrease
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.7$574.61+1.5%$61.22 billion$8.50 billion16.26Upcoming Earnings
Short Interest Increase
News Coverage
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.6$201.58+0.6%$52.18 billion$6.21 billion26.59Earnings Announcement
Analyst Downgrade
News Coverage
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
1.7$16.50+2.6%$52.07 billion$30.17 billion14.60Short Interest Decrease
News Coverage
High Trading Volume
High Trading Volume
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$182.50+0.0%$40.34 billion$6.07 billion59.64
Genmab A/S logo
GMAB
Genmab A/S
1.8$45.06+1.0%$29.59 billion$1.55 billion34.66
BeiGene logo
BGNE
BeiGene
1.7$316.59+1.4%$29.25 billion$308.87 million-23.23Upcoming Earnings
Analyst Revision
News Coverage
Gap Down
Royalty Pharma logo
RPRX
Royalty Pharma
3.0$38.20+0.1%$23.19 billion$2.12 billion23.88Analyst Report
Insider Selling
News Coverage
High Trading Volume
High Trading Volume
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$100.02+2.6%$22.48 billion$2.20 billion86.22Upcoming Earnings
Analyst Upgrade
Insider Selling
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.9$178.94+1.6%$21.03 billion$492.85 million-23.73Upcoming Earnings
News Coverage
Catalent logo
CTLT
Catalent
2.0$119.81+0.4%$20.41 billion$3.09 billion40.34Insider Selling
Elanco Animal Health logo
ELAN
Elanco Animal Health
2.5$36.47+0.4%$17.25 billion$3.27 billion-30.39
Viatris logo
VTRS
Viatris
3.0$14.07+1.6%$17.01 billion$11.95 billion3.02News Coverage
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
3.0$76.73+2.3%$14.02 billion$1.86 billion17.89Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Up
Zai Lab logo
ZLAB
Zai Lab
2.0$144.61+6.1%$13.72 billion$48.96 million-41.79Gap Down
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.4$43.97+2.2%$11.33 billion$284.10 million25.86Short Interest Decrease
Gap Down
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
2.3$9.65+0.4%$10.54 billion$16.66 billion-2.70Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Bausch Health Companies logo
BHC
Bausch Health Companies
2.5$29.25+1.2%$10.48 billion$8.03 billion-10.23Upcoming Earnings
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.8$62.55+0.6%$10.41 billion$2.59 billion40.10Earnings Announcement
Analyst Downgrade
Short Interest Decrease
Analyst Revision
News Coverage
High Trading Volume
High Trading Volume
Grifols logo
GRFS
Grifols
2.1$15.21+2.4%$10.32 billion$6.10 billion15.84
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
3.1$169.52+0.6%$9.65 billion$2.36 billion18.59Upcoming Earnings
CureVac logo
CVAC
CureVac
1.5$49.26+5.3%$9.21 billion$55.83 million-43.98Short Interest Decrease
Gap Up
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.8$160.06+0.1%$8.23 billion$13.40 million-18.61Upcoming Earnings
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$126.01+0.1%$8.20 billion$63.63 million-8.89
United Therapeutics logo
UTHR
United Therapeutics
2.5$181.93+1.3%$8.15 billion$1.48 billion20.10Upcoming Earnings
News Coverage
Positive News
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.2$53.45+1.7%$7.98 billion$8.25 million-12.73Analyst Downgrade
Positive News
HUTCHMED logo
HCM
HUTCHMED
1.4$42.05+2.5%$7.28 billion$227.98 million-46.72Analyst Revision
Gap Down
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
2.0$69.29+1.4%$7.21 billion$87.99 million-64.76Upcoming Earnings
News Coverage
Gap Down
Perrigo logo
PRGO
Perrigo
2.2$48.03+0.3%$6.41 billion$5.06 billion-28.25
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
2.6$118.19+1.1%$6.36 billion$7.94 million-12.53
Legend Biotech logo
LEGN
Legend Biotech
1.6$43.03+2.1%$6.22 billion$75.68 million-30.74Gap Up
I-Mab logo
IMAB
I-Mab
1.4$78.08+2.5%$6.01 billion$236.42 million73.66Unusual Options Activity
News Coverage
Gap Down
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
2.1$67.78+1.7%$5.41 billion$540.10 million-7.59Upcoming Earnings
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
2.5$79.83+0.7%$5.39 billion$271.03 million-25.59Upcoming Earnings
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
2.1$37.14+1.2%$5.24 billion$729 million-10.52Upcoming Earnings
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
2.5$63.99+4.1%$5.15 billion$250.65 million-13.47Analyst Revision
Gap Up
Blueprint Medicines logo
BPMC
Blueprint Medicines
2.5$87.87+3.6%$5.13 billion$793.73 million14.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
Arvinas logo
ARVN
Arvinas
2.4$101.10+6.7%$4.95 billion$21.80 million-30.92Upcoming Earnings
Analyst Upgrade
Insider Selling
Gap Up
TG Therapeutics logo
TGTX
TG Therapeutics
2.3$34.99+2.0%$4.95 billion$150,000.00-13.46Upcoming Earnings
News Coverage
This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.